Abstract
The authors investigated neuropsychiatric symptoms in mild cognitive impairment (MCI) from baseline data of the Investigation in the Delay to Diagnosis of AD with Exelon (InDDEx) study (n = 1,010). Neuropsychiatric symptoms were reported in 59% of subjects (Neuropsychiatric Inventory [NPI]). NPI+ subjects had significantly greater impairment on global, cognitive, and functional scores than NPI- subjects. The presence of neuropsychiatric symptoms appears to be a marker of MCI severity.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Alzheimer Disease / complications
-
Alzheimer Disease / physiopathology
-
Alzheimer Disease / prevention & control*
-
Behavioral Symptoms / complications
-
Behavioral Symptoms / diagnosis*
-
Behavioral Symptoms / physiopathology
-
Carbamates / therapeutic use
-
Cholinesterase Inhibitors / therapeutic use
-
Cognition Disorders / complications
-
Cognition Disorders / diagnosis*
-
Cognition Disorders / physiopathology
-
Female
-
Humans
-
Male
-
Middle Aged
-
Neuropsychological Tests / statistics & numerical data*
-
Phenylcarbamates*
-
Rivastigmine
Substances
-
Carbamates
-
Cholinesterase Inhibitors
-
Phenylcarbamates
-
Rivastigmine